Sugi Predict

Sugi Predict / Compounds / SCHEMBL199961

SCHEMBL199961

SCHEMBL199961

Cc1ccccc1P(c1ccccc1C)c1ccccc1C.Cc1ccccc1P(c1ccccc1C)c1ccccc1C.Cc1ccccc1P(c1ccccc1C)c1ccccc1C.Cc1ccccc1P(c1ccccc1C)c1ccccc1C.[Pd]

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 4/20 0.50
▸ ACHE P22303 3/20 0.50
▸ ALDH1A1 P00352 4/20 0.39
▸ CA1 P00915 2/20 0.39
▸ CA2 P00918 2/20 0.39
▸ CA7 P43166 2/20 0.39
▸ CA9 Q16790 2/20 0.39
▸ CYP3A4 P08684 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ ALKBH5 Q6P6C2 1/20 0.37
▸ FTO Q9C0B1 1/20 0.37
▸ CYP1A2 P05177 2/20 0.36
▸ CYP2A6 P11509 2/20 0.36
▸ MAPT P10636 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ ALOX12 P18054 1/20 0.33
▸ ESR1 P03372 1/20 0.33
▸ TAAR1 Q96RJ0 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7811284 1.00 TSHR (0.50) TSHRACHEALDH1A1CA1CA2
SCHEMBL30058349 1.00 TSHR (0.50) TSHRACHEALDH1A1CA1CA2
SCHEMBL2502467 1.00 TSHR (0.50) TSHRACHEALDH1A1CA1CA2
SCHEMBL29700602 1.00 TSHR (0.50) TSHRACHEALDH1A1CA1CA2
SCHEMBL29464227 1.00 TSHR (0.50) TSHRACHEALDH1A1CA1CA2
SCHEMBL138533 1.00 TSHR (0.50) TSHRACHEALDH1A1CA1CA2
Hydrochloric Acid SCHEMBL290288 0.97 TSHR (0.47) TSHRACHEALDH1A1CA1CA2
SCHEMBL29357701 0.97 TSHR (0.53) TSHRACHEALDH1A1CA1CA2
SCHEMBL4480 0.97 TSHR (0.53) TSHRACHEALDH1A1CA1CA2
SCHEMBL3127305 0.97 TSHR (0.53) TSHRACHEALDH1A1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 317 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110359097-B Method for obtaining On-DNA aromatic hydrocarbon compound through Suzuki coupling reaction in construction of DNA coding compound library 上海药明康德新药开发有限公司 2022-09-20 — — CN claimed
CN-110331447-B Method for preparing On-DNA aryl alkyne compound in construction of DNA coding compound library 上海药明康德新药开发有限公司 2022-05-27 — — CN claimed
EP-3985008-A1 PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR Incyte Holdings Corporation (US) 2022-04-20 — — EP claimed
US-11091480-B2 Crystalline solid forms of a BET inhibitor INCYTE CORPORATION (US) 2021-08-17 — — US claimed
CN-113036036-A Preparation method and application of benzothiadiazole molecular ternary electric storage device 苏州科技大学 2021-06-25 — — CN claimed
CN-112851733-A Method for preparing C-C coupling product based On-DNA aryl diazonium salt intermediate 重庆大学 2021-05-28 — — CN claimed
EP-2964650-B1 PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR INCYTE HOLDINGS CORP (US) 2018-12-05 — — EP claimed
US-9714233-B2 Processes and intermediates for making a JAK inhibitor INCYTE CORPORATION (US) 2017-07-25 — — US claimed
WO-2016088102-A1 PROCESSES FOR THE PREPARATION OF TEDIZOLID PHOSPHATE AND ITS INTERMEDIATES SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2016-06-09 — — WO claimed
US-8987443-B2 Processes and intermediates for making a JAK inhibitor INCYTE CORPORATION (US) 2015-03-24 — — US claimed
US-7964731-B2 Isotopically marked quinoline derivatives as adenosin A3 receptor ligands SANOFI-AVENTIS (FR) 2011-06-21 — — US claimed
EP-2288610-A1 AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS Incyte Corporation (US) 2011-03-02 — — EP claimed
US-7868180-B2 Process for the preparation of sartan derivatives and intermediates useful in such process KRKA, D.D. NOVO MESTO (SI) 2011-01-11 — — US claimed
EP-1814857-B1 ISOTOPICALLY MARKED QUINOLINE DERIVATIVES AS ADENOSIN A3 RECEPTOR LIGANDS SANOFI AVENTIS (FR) 2010-09-01 — — EP claimed
WO-2009114512-A1 AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION (US) 2009-09-17 — — WO claimed
US-20090233903-A1 AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION (US) 2009-09-17 — — US claimed
US-20080312451-A1 Process For the Preparation of Sartan Derivatives and Intermediates Useful in Such Process KRKA, D.D. NOVO MESTO (SK) 2008-12-18 — — US claimed
EP-1764365-A1 A process for the preparation of sartan derivates and intermediates useful in such process KRKA, D.D., Novo Mesto (SI) 2007-03-21 — — EP claimed
US-6884862-B2 Polymer, process for production, composition for film formation containing the same, method of film formation, and insulating film JSR CORPORATION (JP) 2005-04-26 — — US claimed
US-6124421-A A SEMICONDUCTOR DEVICE COMPRISING A DIELECTRIC LAYER DISPOSED OVERLYING A SURFACE, COMPRISES A POLY(ARYLENE ETHER) ALLIEDSIGNAL INC. (US) 2000-09-26 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11091480-B2 Crystalline solid forms of a BET inhibitor BRD1, BRD3, BRD2 TSHR 2475/4885ACHE 4803/4885ALDH1A1 4804/4885
US-20090233903-A1 AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS JAK1, JAK2, JAK3 TSHR 1890/4885ACHE 4608/4885ALDH1A1 3725/4885
US-20080312451-A1 Process For the Preparation of Sartan Derivatives and Intermediates Useful in Such Process MC5R, NPY5R, ADRA1D TSHR 70/4885ACHE 4408/4885ALDH1A1 3228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.